Skip to content
MedsAcross

Medicine

Dotarem 1884.5 mg/5 mL injection

Gadoterate · Intravenous · Guerbet
Available on requestPrescription onlyUS FDA

Dotarem 1884.5 mg/5 mL injection is a prescription medicine containing Gadoterate for intravenous use, marketed by Guerbet, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F)…

Key facts

Active ingredient (INN)
Gadoterate
Brand
Dotarem
Strength
1884.5 mg/5 mL
Dosage form
Injection
Route
Intravenous
Packs
10 vials of 5 mL
Marketing authorisation holder
Guerbet
Manufacturer
Guerbet
Origin register
US FDA, United States
Storage
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Should solidification occur in the vial because of exposure to the cold, bring DOTAREM to room temperature before use. If allowed to stand at room temperature for a minimum of 90 minutes, DOTAREM should return to a clear, colorless to yellow solution.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
V08CA02 Gadoterate
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
20 March 2013
Identifiers
DailyMed set ID e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebcNDC 67684-2000, 67684-2001Application NDA204781

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
10 vial in 1 package / 5 mL in 1 vial67684-2000-0Guerbet31 March 2017
10 vial in 1 package / 5 mL in 1 vial67684-2001-0Guerbet24 October 2019

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 20 March 2013Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Gadoterate 1884.5 mg/5 mL injection.

Compare all 2

Other strengths and forms of Gadoterate

Clinical summary

Gadoterate is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Gadoterate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Gadoterate

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Dotarem 1884.5 mg/5 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.